Source - SMW
Allergy Therapeutics has started its G205 phase II study designed to evaluate the dose-response and safety of its ultra-short course, aluminium free PQ Grass immunotherapy to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

It said the study was anticipated to run for one year and involve approximately 440 patients in more than 50 sites across Germany, Austria and Poland.  

At 9:52am: (LON:AGY) Allergy Therapeutics PLC share price was +0.13p at 37.5p